The University of Southampton
×
Filter your search:
University of Southampton Institutional Repository

Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer: a single technology appraisal

Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer: a single technology appraisal
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer: a single technology appraisal
This report is a critique of the company’s submission (CS) to NICE from Bayer on the clinical effectiveness and cost effectiveness of darolutamide + docetaxel + androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). It identifies the strengths and weakness of the CS.
National Institute for Health and Care Excellence
Hazell, Lorna
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Chinnery, Fay
57bc237a-8d07-4af1-b469-e801dff5715b
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Hazell, Lorna
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Chinnery, Fay
57bc237a-8d07-4af1-b469-e801dff5715b
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67

Hazell, Lorna, Cooper, Keith, Chinnery, Fay, Pickett, Karen, Scott, David Alexander and Shepherd, Jonathan (2023) Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer: a single technology appraisal (Health Technology Assessment) National Institute for Health and Care Excellence 113pp.

Record type: Monograph (Project Report)

Abstract

This report is a critique of the company’s submission (CS) to NICE from Bayer on the clinical effectiveness and cost effectiveness of darolutamide + docetaxel + androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). It identifies the strengths and weakness of the CS.

This record has no associated files available for download.

More information

Published date: 21 June 2023
Related URLs:

Identifiers

Local EPrints ID: 484627
URI: http://eprints.soton.ac.uk/id/eprint/484627
PURE UUID: 3aafebb4-8051-42c3-986e-0ff803b5bb1f
ORCID for Lorna Hazell: ORCID iD orcid.org/0000-0002-5962-0648
ORCID for Keith Cooper: ORCID iD orcid.org/0000-0002-0318-7670
ORCID for Fay Chinnery: ORCID iD orcid.org/0000-0002-8082-9016
ORCID for Karen Pickett: ORCID iD orcid.org/0000-0002-8631-6465
ORCID for David Alexander Scott: ORCID iD orcid.org/0000-0001-6475-8046
ORCID for Jonathan Shepherd: ORCID iD orcid.org/0000-0003-1682-4330

Catalogue record

Date deposited: 17 Nov 2023 18:09
Last modified: 18 Nov 2023 02:58

Export record

Contributors

Author: Lorna Hazell ORCID iD
Author: Keith Cooper ORCID iD
Author: Fay Chinnery ORCID iD
Author: Karen Pickett ORCID iD
Author: David Alexander Scott ORCID iD
Author: Jonathan Shepherd ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information
Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×